- Home
- COLL
as 04-03-2025 4:00pm EST
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
| Founded: | 2002 | Country: | United States |
| Employees: | N/A | City: | STOUGHTON |
| Market Cap: | 910.2M | IPO Year: | 2015 |
| Target Price: | $43.60 | AVG Volume (30 days): | 438.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.86 | EPS Growth: | 43.56 |
| 52 Week Low/High: | $27.28 - $42.29 | Next Earning Date: | 05-08-2025 |
| Revenue: | $631,449,000 | Revenue Growth: | 11.41% |
| Revenue Growth (this year): | 20% | Revenue Growth (next year): | 3.93% |
Stock Insider Trading Activity of Collegium Pharmaceutical Inc. (COLL)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Dreyer Scott | COLL | EVP & Chief Commercial Officer | Mar 20 '25 | Sell | $30.01 | 20,808 | $624,794.18 | 103,613 | |
| Dreyer Scott | COLL | EVP & Chief Commercial Officer | Mar 14 '25 | Sell | $30.00 | 2,255 | $67,661.05 | 103,613 | |
| Tupper Colleen | COLL | EVP & Chief Financial Officer | Mar 14 '25 | Sell | $30.00 | 977 | $29,313.32 | 164,269 | |
| Dreyer Scott | COLL | EVP & Chief Commercial Officer | Mar 11 '25 | Sell | $30.00 | 30,774 | $923,343.10 | 103,613 | |
| Tupper Colleen | COLL | EVP & Chief Financial Officer | Mar 11 '25 | Sell | $30.01 | 10,445 | $313,412.67 | 164,269 | |
| Dreyer Scott | COLL | EVP & Chief Commercial Officer | Mar 6 '25 | Sell | $30.00 | 5,643 | $169,299.49 | 103,613 | |
| Tupper Colleen | COLL | EVP & Chief Financial Officer | Mar 6 '25 | Sell | $30.00 | 3,453 | $103,591.05 | 164,269 | |
| Kuhlmann Shirley R. | COLL | EVP and General Counsel | Mar 4 '25 | Sell | $28.20 | 86,067 | $2,426,633.99 | 108,137 | |
| Kuhlmann Shirley R. | COLL | EVP and General Counsel | Jan 10 '25 | Sell | $33.26 | 27,500 | $908,627.77 | 108,137 |
Latest Collegium Pharmaceutical Inc. News
COLL Breaking Stock News: Dive into COLL Ticker-Specific Updates for Smart Investing
Simply Wall St.
2 days ago
Is Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) 30% ROE Better Than Average?
StockStory
2 days ago
A Look Back at Branded Pharmaceuticals Stocks’ Q4 Earnings: Collegium Pharmaceutical (NASDAQ:COLL) Vs The Rest Of The Pack
Argus Research
2 days ago
COLL: Lowering target price to $31.00
GlobeNewswire
3 days ago
Collegium to Participate in 24th Annual Needham Virtual Healthcare Conference
GlobeNewswire
8 days ago
Collegium to Present Real-World Data at PainConnect 2025, the American Academy of Pain Medicine’s Annual Meeting
GlobeNewswire
9 days ago
Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board
Argus Research
9 days ago
COLL: Raising target price to $32.00
StockStory
14 days ago
Q4 Earnings Highs And Lows: Royalty Pharma (NASDAQ:RPRX) Vs The Rest Of The Branded Pharmaceuticals Stocks
Compare COLL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "COLL Collegium Pharmaceutical Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.